OSAKA, Japan & MONTREAL--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono†) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; "Congruence†) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. In December 2024, we entere. ...